|
|
08.05.25 - 22:33
|
Theriva Biologics Announces Closing of $7.5 Million Public Offering (GlobeNewswire EN)
|
|
ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the closing of its previously announced “reasonable best efforts” public offering of 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant (the “Offering”). The Company received aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants have an exercise price of $1.10 per share, became exercisable immediately upon issuance and expire five years from the issuance date....
|
|
|
07.05.25 - 15:21
|
Theriva Biologics Announces Pricing of $7.5 Million Public Offering (GlobeNewswire EN)
|
|
ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its “reasonable best efforts” public offering for the purchase and sale of up to 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant (the “Offering”). The Company expects to receive aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $1.10 per share, will be exercisable immediately and will expire five years from the issuance date....
|
|
|
05.03.25 - 22:06
|
Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual (GlobeNewswire EN)
|
|
ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Steve Shallcross, Chief Executive Officer, and Manel Cascallo, PhD., General Director will present at the Q1 Investor Summit Virtual. Theriva's management team will participate in 1x1 meetings....
|
|
|
|
01.11.24 - 13:37
|
Pre-market Movers: EPIX, TOVX, VSME, LXRX, ATHA. (AFX)
|
|
CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15. ......
|
|
26.08.24 - 08:33
|
XFRA : SFY0: Aussetzung/Suspension (XETRA)
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
THERIVA BIO. DL-,001 SFY0 US87164U5083 BAW/UFN...
|
|
|
25.08.24 - 21:25
|
XFRA : NEW INSTRUMENT AVAILABLE - 26.08.2024 - US87164U5083 (XETRA)
|
|
Das Instrument SFY0 US87164U5083 THERIVA BIO. DL-,001 EQUITY hat seinen ersten Handelstag am 26.08.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N
The instrument SFY0 US87164U5083 THERIVA BIO. DL-,001 EQUITY has its first trading date on 26.08.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...
|
|
23.08.24 - 16:43
|
XFRA : ISIN CHANGE (XETRA)
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
CA64157G1019 New Age Metals Inc. 23.08.2024 CA64157G2009 New Age Metals Inc. 26.08.2024 Tausch 4:1
US87164U4094 Theriva Biologics Inc. 23.08.2024 US87164U5083 Theriva Biologics Inc. 26.08.2024 Tausch 25:1...
|
|